Loading company…
Shouyao Holdings (Beijing) develops small molecule drugs for cancer and diabetes and is listed on the Shanghai Stock Exchange.
Established in 2016 and based in Beijing, China, the company was previously known as Shouyao Holdings. It holds 159 invention patents and 22 drug pipelines, and its SY-707 candidate, an anaplastic lymphoma kinase inhibitor for lung cancer, is in Phase II trials. Listed on the Shanghai Stock Exchange in March 2022 under number 688197, it plans to use IPO funding for R&D and new drug industrialization bases.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in